Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

This publication has 16 references indexed in Scilit:

• Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
  European Journal Of Cancer, 2004
• A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma
  Clinical Cancer Research, 2004
• Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFN-α2b versus rIFN-γ versus ISCADOR M® versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis
  Published by Elsevier ,2004
• Adjuvant Interferon in High-Risk Melanoma: The AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research Randomized Study of Adjuvant Low-Dose Extended-Duration Interferon Alfa-2a in High-Risk Resected Malignant Melanoma
  Journal of Clinical Oncology, 2004
• Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials
  Cancer Treatment Reviews, 2003
• European approach to adjuvant treatment of intermediate- and high-risk malignant melanoma
  Seminars in Oncology, 2002
• Interferon Alfa Therapy for Malignant Melanoma: A Systematic Review of Randomized Controlled Trials
  Journal of Clinical Oncology, 2002
• Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial
  The Lancet, 2001
• Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases
  The Lancet, 1998
• A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
  The Annals of Statistics, 1988